Liver News and Research

RSS

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).

17 Mar 2010

California jury rules insurer should pay for out-of-state operation; Mass. probe shows insurers' payments can vary widely

The Los Angeles Times: "A Los Angeles jury concluded Monday that Anthem Blue Cross should cover the cost of an out-of-state liver transplant that a California man paid for after the insurer balked. In addition, the jury ordered Blue Cross to pay plaintiff Ephram Nehme's legal expenses, which could dwarf the $206,000 cost of the transplant. Blue Cross approved Nehme's liver transplant in late 2006, and he was on the waiting list at UCLA Medical Center.

17 Mar 2010

International Liver Congress 2010: Achillion Pharmaceuticals' protease inhibitor abstract accepted for presentation

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that its abstract titled "Virological Response, Safety, and Pharmacokinetic Profile Following Single- and Multiple-Dose Administration of ACH-0141625 Protease Inhibitor to Healthy Volunteers and HCV Genotype-1 Patients" has been accepted as a late breaking poster presentation at the International Liver Congress™ 2010 being held April 14-18 in Vienna, Austria.

17 Mar 2010

Despite accomplishments and improvements, cancer remains too common disease in the U.S.

Although there have been achievements in the battle against cancer, including a decrease in the rate of death and new diagnoses, cancer remains one of the leading causes of death in the U.S., with a need for continued improvement in the areas of prevention, detection and treatment, according to a commentary in the March 17 issue of JAMA, a theme issue on cancer.

17 Mar 2010

Researchers evaluate novel organ sharing system that could help save more lives

Saint Louis University's Center for Outcome Research has received a $1 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to review regional kidney and liver distribution in the United States and equalize the access to transplantation among patients with similar stages of organ failure across the country.

17 Mar 2010

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Vertex Pharmaceuticals Incorporated today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010.

17 Mar 2010

Human amniotic fluid skin cells "reprogrammed" to pluripotency

In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.

16 Mar 2010

Bovie Medical reports revenues totalling $6.5M for fourth-quarter 2009

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the fourth quarter and year ended December 31, 2009.

16 Mar 2010

MDS reports revenues of $46M for first-quarter fiscal 2010

MDS Inc., a leading provider of products and services to the global health science markets, today reported financial results and filed its unaudited interim consolidated financial statements and related Management Discussion & Analysis for the three months ended January 31, 2010. In order to simplify our disclosures, we have discontinued the use of non-GAAP measures such as adjusted EBITDA.

16 Mar 2010

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

BeaconEquity.com announces an investment report featuring biotech company StemCells Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

16 Mar 2010

First Edition: March 16, 2010

In today's headlines, ongoing efforts by President Obama and Democratic leaders to press and persuade wavering votes in support of health reform take center stage.

16 Mar 2010

Tips for reducing LDL cholesterol

Cardiovascular disease is the No.1 killer in North America. And high cholesterol is one of the primary risk factors of coronary heart disease and stroke. According to the Heart and Stroke Foundation, almost 40% of Canadian adults are classified as having high blood cholesterol levels.

16 Mar 2010

Study confirms blood-stage infection is due to population mixing and disease evolution

In a paradigm changing discovery, Plasmodium vivax (P. vivax) malaria has been identified in a population historically thought to be resistant to the disease, those who do not express the Duffy blood group protein on their red blood cells, according to researchers from Case Western Reserve University School of Medicine, Pasteur Institute, and the Madagascar Ministry of Health.

16 Mar 2010

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

16 Mar 2010

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new pre-clinical data from its hypercholesterolemia program, performed in collaboration with scientists at the University of Texas Southwestern Medical Center at Dallas. The data were presented at the PCSK9 Conference: From Gene to Therapeutics held in Nantes, France from March 11-13, 2010.

15 Mar 2010

Researchers discover microtentacles that play key role in spreading cancer to distant locations in body

Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center have discovered that "microtentacles," or extensions of the plasma membrane of breast cancer cells, appear to play a key role in how cancers spread to distant locations in the body. Targeting these microtentacles might prove to be a new way to prevent or slow the growth of these secondary cancers, the scientists say.

15 Mar 2010

U.S. prescribing information for PLAVIX revised

Sanofi-aventis U.S. and Bristol-Myers Squibb Company today announced revisions to the U.S. prescribing information for PLAVIX® (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite.

15 Mar 2010

FDA warns patients and physicians about the efficacy of Plavix treatment

The U.S. Food and Drug Administration today added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and health care professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.

15 Mar 2010

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.

12 Mar 2010

Development of promising new cancer therapies: OICR announces $1M investment

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced an investment of $1 million towards the development of two new promising cancer therapies.

12 Mar 2010

Liver News and Research

Pathway Genomics' personal Genetic Health Report now available

California jury rules insurer should pay for out-of-state operation; Mass. probe shows insurers' payments can vary widely

International Liver Congress 2010: Achillion Pharmaceuticals' protease inhibitor abstract accepted for presentation

Despite accomplishments and improvements, cancer remains too common disease in the U.S.

Researchers evaluate novel organ sharing system that could help save more lives

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Human amniotic fluid skin cells "reprogrammed" to pluripotency

Bovie Medical reports revenues totalling $6.5M for fourth-quarter 2009

MDS reports revenues of $46M for first-quarter fiscal 2010

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

First Edition: March 16, 2010

Tips for reducing LDL cholesterol

Study confirms blood-stage infection is due to population mixing and disease evolution

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Researchers discover microtentacles that play key role in spreading cancer to distant locations in body

U.S. prescribing information for PLAVIX revised

FDA warns patients and physicians about the efficacy of Plavix treatment

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Development of promising new cancer therapies: OICR announces $1M investment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News